Precision Medicine Online’s Post

#ADC #Toxins Antibody-Drug Conjugates (ADCs) are groundbreaking cancer treatments comprising a monoclonal antibody, a linker, and a toxin. By targeting tumor cells while sparing healthy ones, they offer precision and effectiveness. The choice of toxin, whether microtubule inhibitors or DNA-damaging agents, is crucial for their efficacy and safety. Our latest blog post provides a concise overview of ADC toxins and their mechanisms of action. 1. Characteristics of ADC Payloads 2. Microtubule Inhibitors: Potent “Warheads” in ADC Drugs 3. DNA Inhibitors 4. Other ADC Toxins 5. DIMA Biotech: Empowering ADC Drug Development Read more: https://lnkd.in/eE_d6DUh

ADCs are a promising class of cancer treatments with an accelerating number of FDA approvals and a rapidly growing market size. This article discusses issues relating to deals and licensing for ADCs/Antibody therapeutics. #technology

ADCs are a promising class of cancer treatments with an accelerating number of FDA approvals and a rapidly growing market size. This article discusses issues relating to deals and licensing for ADCs/Antibody therapeutics. #technology

ADCs are a promising class of cancer treatments with an accelerating number of FDA approvals and a rapidly growing market size. This article discusses issues relating to deals and licensing for ADCs/Antibody therapeutics. #technology

ADCs are a promising class of cancer treatments with an accelerating number of FDA approvals and a rapidly growing market size. This article discusses issues relating to deals and licensing for ADCs/Antibody therapeutics. #technology

ADCs are a promising class of cancer treatments with an accelerating number of FDA approvals and a rapidly growing market size. This article discusses issues relating to deals and licensing for ADCs/Antibody therapeutics. #technology

ADCs are a promising class of cancer treatments with an accelerating number of FDA approvals and a rapidly growing market size. This article discusses issues relating to deals and licensing for ADCs/Antibody therapeutics. #technology

InnoCare to conduct trial of B-cell lymphoma-2 inhibitor ICP-248 in combo with BTK inhibitor orelabrutinib for lymphocytic leukaemia

Immune checkpoint inhibitors (ICIs) have become pivotal in cancer treatment, with Chinese pharmaceutical firms advancing the development of PD-1 and PD-L1 inhibitors for various cancers. Now, several of these companies are eyeing or already making moves into the US and European markets. BeiGene, Hengrui Medicine, Shanghai Junshi Biosciences Co Ltd, and Innovent Biologics lead the charge in PD-1/PD-L1 research in China, boasting several approved and ongoing assets. In the fiercely competitive landscape of PD-1/PD-L1 therapeutics, success hinges on innovation. Companies must strive to carve out unique approaches and target areas where current treatments fall short. Pioneering novel measures or addressing unmet needs can set businesses apart in this intense arena. Noteworthy additions to the array of PD-1/PD-L1 inhibitors include spartalizumab (Novartis), sasanlimab (Pfizer), zimberelimab (Arcus Biosciences), INCB99280 (Incyte Corporation), balstilimab (Agenus), among others. To know more, visit: https://lnkd.in/gcK2Dksq #ImmuneCheckpointInhibitors #ICIs #cancertreatment #PD1inhibitors #PDL1inhibitors #ChinesePharma #USmarket #Europeanmarket #Beigene #HengruiMedicine #JunshiBiosciences #InnoventBiologics #innovation #competitiveness #noveltreatments #spartalizumab #sasanlimab #zimberelimab #INCB99280 #balstilimab

Hepatic Tumor Treatment Drugs, Clinical Trials, Pipeline Insights, and Companies 2024: DelveInsight’s, “Hepatic Tumor Pipeline Insight 2024”report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Hepatic Tumor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, … Continue reading → #PharmaceuticalsBiotech